Dual molecular delivery of oligonucleotides and peptide containing conjugates

US10532068B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Steven L. Colletti · Princeton Junction, US
• Thomas J. Tucker · North Wales, US
• David M. Tellers · Lansdale, US
• Boyoung Kim · Lexington, US
• Rob Burke · San Diego, US
• Kathleen B. Calati · Hillsborough Township, US
• Matthew G. Stanton · Marlton, US
• Rubina G. Parmar · Cambridge, US
• Jeffrey Aaronson · Johnstown, US
• Weimin Wang · Hangzhou City, CN

Key dates

• Filing date: May 8, 2018
• Grant date: Jan 14, 2020
• Expiry date: May 8, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.